EP2903643A4 - Treatment of psychiatric conditions - Google Patents

Treatment of psychiatric conditions

Info

Publication number
EP2903643A4
EP2903643A4 EP13843079.8A EP13843079A EP2903643A4 EP 2903643 A4 EP2903643 A4 EP 2903643A4 EP 13843079 A EP13843079 A EP 13843079A EP 2903643 A4 EP2903643 A4 EP 2903643A4
Authority
EP
European Patent Office
Prior art keywords
treatment
psychiatric conditions
psychiatric
conditions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP13843079.8A
Other languages
German (de)
French (fr)
Other versions
EP2903643A1 (en
Inventor
John Simard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Biotech Inc
Original Assignee
Xbiotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xbiotech Inc filed Critical Xbiotech Inc
Publication of EP2903643A1 publication Critical patent/EP2903643A1/en
Publication of EP2903643A4 publication Critical patent/EP2903643A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
EP13843079.8A 2012-10-04 2013-10-01 Treatment of psychiatric conditions Withdrawn EP2903643A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261709741P 2012-10-04 2012-10-04
PCT/US2013/062899 WO2014055541A1 (en) 2012-10-04 2013-10-01 Treatment of psychiatric conditions

Publications (2)

Publication Number Publication Date
EP2903643A1 EP2903643A1 (en) 2015-08-12
EP2903643A4 true EP2903643A4 (en) 2016-06-15

Family

ID=50435375

Family Applications (1)

Application Number Title Priority Date Filing Date
EP13843079.8A Withdrawn EP2903643A4 (en) 2012-10-04 2013-10-01 Treatment of psychiatric conditions

Country Status (7)

Country Link
EP (1) EP2903643A4 (en)
JP (3) JP6750941B2 (en)
KR (1) KR20150064091A (en)
CN (1) CN104684581A (en)
AU (1) AU2013327498B2 (en)
CA (1) CA2886757C (en)
WO (1) WO2014055541A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6324720B2 (en) 2010-06-18 2018-05-16 エックスバイオテク, インコーポレイテッドXbiotech, Inc. Arthritis treatment
WO2012027324A2 (en) 2010-08-23 2012-03-01 Xbiotech, Inc. Treatment for neoplastic diseases
US9724409B2 (en) 2011-04-01 2017-08-08 Xbiotech, Inc. Treatment of inflammatory skin disease
EP2750709B1 (en) 2011-09-23 2018-08-15 XBiotech, Inc Cachexia treatment
US9545441B2 (en) 2012-09-18 2017-01-17 Xbiotech, Inc. Treatment of diabetes
SG11201907159SA (en) 2017-02-16 2019-09-27 Xbiotech Inc Treatment of hidradenitis suppurativa

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9405021D0 (en) * 1994-03-15 1994-04-27 Unilever Plc Skin treatment composition
US5455234A (en) * 1994-03-16 1995-10-03 Ahluwalia; Gurpreet S. Inhibition of hair growth
JP2002226457A (en) * 2001-02-02 2002-08-14 Ajinomoto Co Inc New cystine derivative and inflammation factor activation inhibitor
JP5670318B2 (en) * 2008-05-30 2015-02-18 エックスバイオテク, インコーポレイテッドXbiotech, Inc. Interleukin 1α antibody and useful methods
US8383778B2 (en) * 2009-01-29 2013-02-26 Abbvie Inc. IL-1 binding proteins
DK2694107T3 (en) * 2011-04-01 2018-12-10 Xbiotech Inc TREATMENT OF DERMATOLOGICAL DISORDERS
US9724409B2 (en) * 2011-04-01 2017-08-08 Xbiotech, Inc. Treatment of inflammatory skin disease

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
CARRASCO DANIEL ET AL: "An Open Label, Phase 2 Study of MABp1 Monotherapy for the Treatment of Acne Vulgaris and Psychiatric Comorbidity", JOURNAL OF DRUGS IN DERMATOLOGY, STRATEGIC COMMUNICATION IN DERMATOLOGY, NEW YORK, NY, US, vol. 14, no. 6, 1 June 2015 (2015-06-01), pages 560 - 564, XP009188540, ISSN: 1545-9616 *
CHARLES A. DINARELLO ET AL: "Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases", NATURE REVIEWS DRUG DISCOVERY, vol. 11, no. 8, 1 August 2012 (2012-08-01), pages 633 - 652, XP055051238, ISSN: 1474-1776, DOI: 10.1038/nrd3800 *
GRAHAME V ET AL: "The psychological correlates of treatment efficacy in acne", DERMATOLOGY AND PSYCHOSOMATICS 2002 CH, vol. 3, no. 3, 2002, pages 119 - 125, XP009189887, ISSN: 1422-9196 *
K. SZABÓ ET AL: "Interleukin-1A +4845(G> T) polymorphism is a factor predisposing to acne vulgaris", TISSUE ANTIGENS., vol. 76, no. 5, 11 November 2010 (2010-11-11), DK, pages 411 - 415, XP055270523, ISSN: 0001-2815, DOI: 10.1111/j.1399-0039.2010.01530.x *
ROSSI SILVIA ET AL: "Interleukin-1 beta Causes Anxiety by Interacting with the Endocannabinoid System", JOURNAL OF NEUROSCIENCE, vol. 32, no. 40, 3 October 2012 (2012-10-03), pages 13896 - 13905, XP002757320, ISSN: 0270-6474 *
RUBINOW D R ET AL: "Reduced anxiety and depression in cystic acne patients after successful treatment with oral isotretinoin", JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, MOSBY, INC, US, vol. 17, no. 1, 1 July 1987 (1987-07-01), pages 25 - 32, XP025650586, ISSN: 0190-9622, [retrieved on 19870701], DOI: 10.1016/S0190-9622(87)70166-2 *
YESIM KAYMAK ET AL: "Comparison of depression, anxiety and life quality in acne vulgaris patients who were treated with either isotretinoin or topical agents", INTERNATIONAL JOURNAL OF DERMATOLOGY, vol. 48, no. 1, 1 January 2009 (2009-01-01), UK, pages 41 - 46, XP055269926, ISSN: 0011-9059, DOI: 10.1111/j.1365-4632.2009.03806.x *

Also Published As

Publication number Publication date
AU2013327498A1 (en) 2015-04-02
CN104684581A (en) 2015-06-03
EP2903643A1 (en) 2015-08-12
JP2015531396A (en) 2015-11-02
CA2886757C (en) 2022-04-05
JP6750941B2 (en) 2020-09-02
CA2886757A1 (en) 2014-04-10
KR20150064091A (en) 2015-06-10
WO2014055541A1 (en) 2014-04-10
AU2013327498B2 (en) 2018-06-28
JP2020143133A (en) 2020-09-10
JP2022177132A (en) 2022-11-30

Similar Documents

Publication Publication Date Title
EP2723384A4 (en) Treatment of proteinopathies
EP2813073A4 (en) Adaptive region of interest
HK1205759A1 (en) Treatment of biomass
GB201506561D0 (en) Treatment of amblyopia
HK1209767A1 (en) Purification of iduronate-2-sulfatase -2-
HK1214128A1 (en) Treatment of cancer
HRP20181000T1 (en) Methods of treating hair related conditions
HK1202053A1 (en) Treatment of liver conditions
EP2903643A4 (en) Treatment of psychiatric conditions
GB201217892D0 (en) Treatment of cancer
HK1204956A1 (en) Treatment of cancer
GB201309274D0 (en) Treatment Of Fuel
ZA201501038B (en) Treatment of wax
EP2892529A4 (en) Uses of (-)-perhexiline
GB201308466D0 (en) Improved process for treatment of minewater
EP2812338A4 (en) Method of treatment of nasopharyngeal caner
EP2897633A4 (en) Treatment of pain by inhibition of usp5 de-ubiquitinase
GB201207907D0 (en) Treatment of depression
GB201217890D0 (en) Treatment of cancer
GB201221118D0 (en) Methods of treatment
GB201216740D0 (en) Methods of treatment
GB201216748D0 (en) Methods of treatment
GB201206324D0 (en) Methods of treatment
GB201206330D0 (en) Methods of treatment
GB201206325D0 (en) Methods of treatment

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20150316

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

RA4 Supplementary search report drawn up and despatched (corrected)

Effective date: 20160518

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 16/24 20060101ALI20160509BHEP

Ipc: A61K 39/395 20060101AFI20160509BHEP

Ipc: A61P 17/10 20060101ALI20160509BHEP

Ipc: A61P 25/00 20060101ALI20160509BHEP

RIN1 Information on inventor provided before grant (corrected)

Inventor name: SIMARD, JOHN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20200702

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: JANSSEN BIOTECH, INC.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20230915